ethyl 6-bromo-2-methylhexanoate | 141748-49-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ethyl 6-bromo-2-methylhexanoate
• CAS: 141748-49-4
• 化学式: C₉H₁₇BrO₂
• 分子量: 237.137
• InChiKey: QGCBQGZBRIRCHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ethyl 6-bromo-2-methylhexanoate 在 氢氧化钾 、 silver carbonate 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 38.0h， 生成 2-methyl-6-<<4-(4-methylphenyl)-6-phenyl-2-pyridyl>oxy>hexanoic acid
  参考文献：
  名称：

  .omega.-[(4,6-Diphenyl-2-pyridyl)oxy]alkanoic acid derivatives: a new family of potent and orally active LTB4 antagonists

  摘要：

  A series of omega-[(4,6-diphenyl-2-pyridyl)oxy]alkanoic acid derivatives was prepared which inhibited the binding of leukotriene B4 to its receptors on guinea pig spleen membranes and on human polymorphonuclear leukocytes (PMNs) and selectively antagonized the LTB4-induced elastase release in human PMNs. On the basis of these three screens, a structure-activity relationship was investigated. Alpha-Substitution on the carboxylic acid side chain led to only small changes in the binding affinities but greatly enhanced the LTB4 antagonist activity. Substitution on the phenyl rings was also evaluated. The terminal carboxylic acid function can be replaced by a tetrazole ring without loss in activity. The beat in vitro LTB4 antagonists of this series were investigated in vivo in the inhibition of LTB4-induced leukopenia in rabbits. Compound 9b (RP69698) displayed potent LTB4 antagonist activity, after oral administration, with an ED50 value of 6.7 mg/kg.

  DOI：

  10.1021/jm00101a008
• 作为产物：
  描述：

  甲基丙烯酸乙酯 在 三丁基膦 、 溶剂黄146 、 copper(I) bromide 、 锌 作用下， 以 四氢呋喃 为溶剂， 反应 22.0h， 生成 ethyl 6-bromo-2-methylhexanoate
  参考文献：
  名称：

  Mitani, Michiharu; Hirayama, Hiroyuki, Journal of Chemical Research, Miniprint, 1993, # 7, p. 1562 - 1572

  摘要：

  DOI：

文献信息

• FUSED AMINO PYRIDINE AS HSP90 INHIBITORS
  申请人：Cai Xiong

  公开号：US20080234314A1

  公开（公告）日：2008-09-25

  The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.

  本发明涉及含有融合氨基吡啶核的HSP90抑制剂，可用作HSP90的抑制剂，以及它们在治疗HSP90相关疾病和紊乱，如癌症、自身免疫疾病或神经退行性疾病中的用途。
• Substituted bicyclic bis-aryl compounds exhibiting selective leukotriene
  申请人：Rhone-Poulenc Rorer S.A.

  公开号：US05366982A1

  公开（公告）日：1994-11-22

  This invention relates to compounds having selective LTB.sub.4 antagonist properties, compositions comprising said compounds and methods for the treatment of disorders involving LTB.sub.4 agonist-mediated activity utilizing said compositions wherein the compounds are described by the general formula ##STR1## and pharmaceutically acceptable salts thereof.

  本发明涉及具有选择性LTB.sub.4拮抗性的化合物，包括所述化合物的组合物以及利用所述组合物治疗涉及LTB.sub.4激动剂介导活性的疾病的方法，其中所述化合物由一般公式##STR1##和其药用可接受的盐描述。
• Substituted quinolyl compounds exhibiting selective leukotriene B.sub.4
  申请人：Rhone-Poulenc Rorer S.A.

  公开号：US05492915A1

  公开（公告）日：1996-02-20

  This invention relates to compounds having selective LTB.sub.4 antagonist properties. Therapeutic compositions comprising said compounds and methods for the treatment of disorders involving LTB.sub.4 agonist-mediated activity utilizing said compositions wherein the compounds are described by the formula ##STR1## wherein R.sub.4, X, R, Y, R', Q, m and n are herein defined, and pharmaceutically acceptable salts thereof.

  本发明涉及具有选择性LTB.sub.4拮抗剂特性的化合物。包括该化合物的治疗组合物和使用该组合物治疗涉及LTB.sub.4激动剂介导的活性的疾病的方法，其中该化合物由以下式子描述：##STR1## 其中R.sub.4、X、R、Y、R'、Q、m和n在此定义，并且其药学上可接受的盐。
• Fused amino pyridine as HSP90 inhibitors
  申请人：Curis, Inc.

  公开号：US10035797B2

  公开（公告）日：2018-07-31

  The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.

  本发明涉及含有融合氨基吡啶核心的 HSP90 抑制剂，这些抑制剂可用作 HSP90 的抑制剂，并可用于治疗与 HSP90 相关的疾病，如癌症、自身免疫性疾病或神经退行性疾病。
• Labaudiniere Richard, Dereu Norbert, Cavy Francoise, Guillet Marie-Christ+, J. Med. Chem., 35 (1992) N 23, S 4315-4324
  作者：Labaudiniere Richard, Dereu Norbert, Cavy Francoise, Guillet Marie-Christ+

  DOI：——

  日期：——